Search Results
Department of Medicine, Endocrinology Service, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Fernanda Andrade in
Google Scholar
PubMed
Search for other papers by Danielle Probstner in
Google Scholar
PubMed
Search for other papers by Marcus Decnop in
Google Scholar
PubMed
Search for other papers by Daniel Bulzico in
Google Scholar
PubMed
Search for other papers by Denise Momesso in
Google Scholar
PubMed
Department of Medicine, Endocrinology Service, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Search for other papers by Mario Vaisman in
Google Scholar
PubMed
Department of Medicine, Endocrinology Service, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Objective: Bone metastases bring greater morbi-mortality to patients with differentiated thyroid carcinoma (DTC). Treatment was limited to radioactive iodine (RAI) and local approaches. Currently, bisphosphonates are included in the therapeutic arsenal. The aim of this study is to evaluate the impact of bone metastases and their treatment with zoledronic acid (ZA) and RAI therapy. Methods: We retrospectively review 50 DTC patients with structurally evident bone metastases followed in a tertiary cancer center from 1994 to 2018. Clinical-pathologic characteristics, skeletal related events (SRE), and therapeutic approaches were recorded. Results: Among the 50 patients analyzed, 22 underwent ZA adjuvant therapy and 28 did not. Mortality rate was 44%. Those patients presented SREs more frequently (90.9 vs. 67.9% the survival group, p = 0.05) and also had a greater number of bone lesions (40.9 vs. 10.7% had more than 6 metastatic sites, p = 0.03). The same group of patients was analyzed before and after therapy with ZA and the incidence of SRE decreased from 1.81 (0–8) before therapy to 0.29 (0–7) after therapy (p = 0.006). Comparing similar groups of 22 patients treated with ZA with 28 patients not treated, there was a trend of better overall survival (OS) in the group that received this drug (147 vs. 119 months, p = 0.06) and significantly improvement when bone metastases were RAI avid 155 (125–185) versus 120 (85–157) months, p < 0.01. Conclusion : ZA can successfully diminish the chance of having new SRE and possibly affect OS in DTC patients with bone metastases. The positive impact of RAI adjuvant treatment on OS is directly associated with RAI uptake.
Endocrinology Service, Department of Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Renata Alencar in
Google Scholar
PubMed
Search for other papers by Daniel Barretto Kendler in
Google Scholar
PubMed
Search for other papers by Fernanda Andrade in
Google Scholar
PubMed
Search for other papers by Carla Nava in
Google Scholar
PubMed
Search for other papers by Daniel Bulzico in
Google Scholar
PubMed
Search for other papers by Cencita Cordeiro de Noronha Pessoa in
Google Scholar
PubMed
Endocrinology Service, Department of Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Endocrinology Service, Department of Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Objective: Medullary thyroid carcinoma (MTC) is a rare disease, and its classic tumor marker is calcitonin. However, recently, very aggressive cases have been reported to also secrete carbohydrate antigen 19-9 (CA19-9), and its role as a marker of worse prognosis has been questioned. The aim of this study was to analyze the relationship between CA19-9 serum levels and MTC outcomes. Methods: We retrospectively reviewed 122 MTC patients followed in a tertiary cancer center from 1985 to 2017. Clinical-pathologic characteristics, therapeutic approaches, and outcomes were recorded and CA19-9 was collected. Results: Of the 122 patients included in the study, 48 had distant metastases, and at the end of follow-up 18.1% had structural persistent disease and 32.7% had progressive disease. CA19-9 was significantly higher in those who had disease progression than in those who had not (21.4 [14.3–110.9] vs. 7.27 [0.6–44.75] U/mL, p = 0.01) and was also higher in patients who died from MTC (18.4 [14.3–110.9] vs. 7.59 [0.6–67.8] U/mL, p < 0.001). Furthermore, using a ROC curve analysis, the cutoff point for CA19-9 in MTC patients was lower than that observed in pancreatic tumors. Conclusion: CA19-9 might have a role as a prognostic factor in addition to calcitonin and carcinoembryonic antigen in metastatic MTC.
Search for other papers by Julia Ramalho Amalio da Silva Breder in
Google Scholar
PubMed
Search for other papers by Paulo Alonso Garcia Alves in
Google Scholar
PubMed
Search for other papers by Mario Lucio Araújo in
Google Scholar
PubMed
Search for other papers by Barbara Pires in
Google Scholar
PubMed
Search for other papers by Priscila Valverde in
Google Scholar
PubMed
Search for other papers by Daniel Alves Bulzico in
Google Scholar
PubMed
Search for other papers by Fernanda Andrade Accioly in
Google Scholar
PubMed
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Search for other papers by Mario Vaisman in
Google Scholar
PubMed
Endocrinology Department, Instituto Nacional do Cancer do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Objective
A sharp increase in pediatric thyroid cancer incidence is observed during adolescence, driven mainly by girls. Differences in disease presentation across sexual maturity stages raise the question of whether sex steroids have a role in the heterogeneity. The aims of this study were to analyze the influence of puberty and sex on clinical presentation and prognosis and to evaluate the correlation between the expression of sex hormone receptors.
Design and methods
Clinical records and immunohistochemical of specimens from 79 patients were analyzed. Puberty was analyzed by two criteria: end of puberty and beginning, in which the age of 10 was the cutoff.
Results
Postpubertal were more frequently classified as having low-risk disease and a lower frequency of persistent disease, especially when the completion of puberty was used as the criteria. Male sex was associated with a higher risk of persistent disease at the end of the observation period. Estrogen receptor α positivity was low in the entire sample, while progesterone receptor positivity was positive in 30% of the cases. Female hormone receptor expression was not associated with sex, American Thyroid Association risk score, persistent structural disease, or pubertal status.
Conclusion
Our study showed that the completion of puberty correlated best with the clinical behaviour of pediatric thyroid cancer. It was also shown that postpubertal patients have a less aggressive initial presentation and better outcomes. However, this observation could not be explained by the expression of estrogen and progesterone receptors in the primary tumors.
Department of Endocrinology, Universidade Federal do Rio de Janeiro – UFRJ, Faculdade de Medicina, Rio de Janeiro, RJ, Brazil
Search for other papers by Marise Codeco de Andrade Barreto in
Google Scholar
PubMed
Search for other papers by Natalia Treistman in
Google Scholar
PubMed
Search for other papers by Lara Bessa Campelo Pinheiro Cavalcante in
Google Scholar
PubMed
Search for other papers by Daniel Bulzico in
Google Scholar
PubMed
Search for other papers by Fernanda Accioly de Andrade in
Google Scholar
PubMed
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Department of Endocrinology, Universidade Federal do Rio de Janeiro – UFRJ, Faculdade de Medicina, Rio de Janeiro, RJ, Brazil
Search for other papers by Paulo Alonso Garcia Alves Junior in
Google Scholar
PubMed
Department of Endocrinology, Universidade Federal do Rio de Janeiro – UFRJ, Faculdade de Medicina, Rio de Janeiro, RJ, Brazil
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Introduction
Treatment of patients with pediatric differentiated thyroid cancer (DTC) often involves radioiodine (RAI), which is associated with increased risks of short- and long-term adverse outcomes. The impact of RAI treatment on the female reproductive system remains uncertain. Anti-Müllerian hormone (AMH) is a marker of ovarian reserve and is related to fertility.
Objective
The aim was to analyze the association between RAI and serum AMH level in women treated with RAI.
Methods
We evaluated women with pediatric DTC treated with RAI at the age of ≤19 years. Serum AMH was measured.
Results
The study included 47 patients with a mean age of 25.1 years (12.4–50.8) at AMH measurement and follow-up of 11.8 ± 8.4 years. The mean RAI administered was 235 mCi (30–1150). Sixteen (34%) received multiple RAI doses (471 ± 215 mCi). Mean AMH level was 2.49 ng/mL (0.01–7.81); the level was 1.57 ng/mL (0.01–7.81) after multiple RAI doses and 2.99 ng/mL (0.01–6.63) after a single RAI dose (P = 0.01). Patients who received a cumulative RAI lower than 200 mCi had higher AMH levels (2.23 ng/mL, 0.39–7.81) than those who received more (1.0 ng/mL, 0.01–6.63; P = 0.02). In patients with similar cumulative RAI activities, administration of multiple RAI doses was significantly and independently associated with AMH level lower than the reference range for age (HR: 5.9, 1.55–52.2, P = 0.014) after age adjustments.
Conclusion
Levels of AMH were lower after multiple RAI doses, especially after a cumulative RAI dose above 200 mCi. More studies are needed to clarify the impact of RAI on fertility considering its cumulative activity and treatment strategy.
